Sign In

Communications of the ACM

ACM TechNews

Baidu in Partnership with Sanofi to Use Its Algorithm in mRNA Vaccine, Therapy Development

View as: Print Mobile App Share:

To catch up with RNA vaccine technology, the world's fifth-largest pharmaceutical company, France-based Sanofi, has decided to rely on Baidu's algorithms.

Credit: Joel Saget/AFP

Baidu has licensed its algorithm for messenger RNA (mRNA) sequencing to Sanofi SA, the Chinese tech giant's first commercial deal with a global drugmaker.

Sanofi, which was beaten by BioNTech/Pfizer and Moderna in the race to develop COVID-19 vaccines, plans to use the technology to design vaccine and therapeutic products for other infectious diseases.

The algorithm can generate a large number of optimized mRNA sequences.

Baidu's Huang Liang cited research indicating the algorithm could be more suitable for vaccine and therapeutic drug development than standard algorithms.

Said Huang, "The fact that this agreement includes milestone payments shows that [Sanofi] has great confidence in bringing candidates developed with [the] Baidu algorithm into clinical trials and to the market."

From Reuters
View Full Article


Abstracts Copyright © 2021 SmithBucklin, Washington, DC, USA


No entries found

Sign In for Full Access
» Forgot Password? » Create an ACM Web Account